Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

SOCS3 inhibiting JAK-STAT pathway enhances oncolytic adenovirus efficacy by potentiating viral replication and T-cell activation

Cancer Gene Therapy volume 31, pages 397–409 (2024)Cite this article

Subjects

Abstract

Oncolytic viruses (OVs) are emerging as a potentially useful treatment for malignancies due to the capabilities of direct oncolysis and immune induction. Improving the replication of OVs is an effective approach to enhance the oncolytic effects. Here, we observed that cancer cells with deficiencies in JAK-STAT pathway showed greater sensitivity to oncolytic adenovirus (oAd), and JAK inhibitor could enhance the replication of oAd. Therefore, we constructed a novel oAd expressing SOCS3, a major negative regulator of JAK-STAT pathway, and confirmed that oAd-SOCS3 exhibited a more significant antitumor effect than oAd-Ctrl both in vitro and in vivo. Mechanistically, SOCS3 inhibited the activation of JAK-STAT pathway, resulting in stronger tumor selective replication of oAd and downregulated expression of PD-L1 on cancer cells as well. Both benefits could collectively awaken antitumor immunity. This study highlights the importance of JAK-STAT pathway in viral replication and confirms the treatment of oAd-SOCS3 in potential clinical applications.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Loss of function in JAK-STAT pathway increased sensitivity to oAd.
Fig. 2: Construction and characteristics of oAd-SOCS3.
Fig. 3: Viral replication of oAd-SOCS3 in vitro.
Fig. 4: oAd-SOCS3 improved oncolytic virotherapy of cancer in a breast cancer xenograft model.
Fig. 5: oAd-SOCS3 mediated oncolysis increased anti-tumor immune response.
Fig. 6: The replication-deficient Ad-SOCS3 demonstrated a limited ability to control tumor growth.

Similar content being viewed by others

Data availability

The data and materials used in this study are available from the corresponding authors upon reasonable request.

References

  1. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Kessler T, Wick W. Oncolytic virotherapy: potentially a game-changing tumor treatment. Cancer Cell. 2021;39:753–5.

    Article  CAS  PubMed  Google Scholar 

  3. Koch J, Schober SJ, Hindupur SV, Schoning C, Klein FG, Mantwill K, et al. Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus. Nat Commun. 2022;13:4689.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  4. Macedo N, Miller DM, Haq R, Kaufman HL. Clinical landscape of oncolytic virus research in 2020. J Immunother Cancer. 2020;8:e001486.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8:156.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Niemann J, Kuhnel F. Oncolytic viruses: adenoviruses. Virus Genes. 2017;53:700–6.

    Article  CAS  PubMed  Google Scholar 

  7. Han Z, Hong Z, Gao Q, Chen C, Hao Z, Ji T, et al. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer. Hum Gene Ther. 2012;23:32–45.

    Article  CAS  PubMed  Google Scholar 

  8. Dai Y, Zhao XJ, Li F, Yuan Y, Yan DM, Cao H, et al. Truncated bid regulates cisplatin response via activation of mitochondrial apoptosis pathway in ovarian cancer. Hum Gene Ther. 2020;31:325–38.

    Article  CAS  PubMed  Google Scholar 

  9. Li F, Yuan Y, Dai Y, Cheng T, Cao H, Yan D, et al. M11: a tropism-modified oncolytic adenovirus arming with a tumor-homing peptide for advanced ovarian cancer therapies. Hum Gene Ther. 2022;33:262–74.

    Article  CAS  PubMed  Google Scholar 

  10. Anghelina D, Lam E, Falck-Pedersen E. Diminished innate antiviral response to adenovirus vectors in cGAS/STING-deficient mice minimally impacts adaptive immunity. J Virol. 2016;90:5915–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Stein SC, Lam E, Falck-Pedersen E. Cell-specific regulation of nucleic acid sensor cascades: a controlling interest in the antiviral response. J Virol. 2012;86:13303–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Aref S, Castleton AZ, Bailey K, Burt R, Dey A, Leongamornlert D, et al. Type 1 interferon responses underlie tumor-selective replication of oncolytic measles virus. Mol Ther. 2020;28:1043–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Nguyen TT, Ramsay L, Ahanfeshar-Adams M, Lajoie M, Schadendorf D, Alain T, et al. Mutations in the IFNgamma-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment. Clin Cancer Res. 2021;27:3432–42.

    Article  CAS  PubMed  Google Scholar 

  14. Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem. 1995;270:15974–8.

    Article  CAS  PubMed  Google Scholar 

  15. Li Q, Tan F, Wang Y, Liu X, Kong X, Meng J, et al. The gamble between oncolytic virus therapy and IFN. Front Immunol. 2022;13:971674.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ahmed M, Cramer SD, Lyles DS. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology. 2004;330:34–49.

    Article  CAS  PubMed  Google Scholar 

  17. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4:263–75.

    Article  CAS  PubMed  Google Scholar 

  18. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett. 2007;254:178–216.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Nguyên TL, Abdelbary H, Arguello M, Breitbach C, Leveille S, Diallo JS, et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA. 2008;105:14981–6.

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  20. Bommareddy PK, Aspromonte S, Zloza A, Rabkin SD, Kaufman HL. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Sci Transl Med. 2018;10:eaau0417.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Xiao J, Liang J, Fan J, Hou P, Li X, Zhang H, et al. CDK4/6 inhibition enhances oncolytic virus efficacy by potentiating tumor-selective cell killing and T-cell activation in refractory glioblastoma. Cancer Res. 2022;82:3359–74.

    Article  CAS  PubMed  Google Scholar 

  22. Xiao X, Liang J, Huang C, Li K, Xing F, Zhu W, et al. DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. Nat Commun. 2018;9:4342.

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  23. Zhang J, Liu Y, Tan J, Zhang Y, Wong CW, Lin Z, et al. Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC. Oncogene. 2021;40:4783–95.

    Article  CAS  PubMed  Google Scholar 

  24. Heppler LN, Frank DA. Targeting oncogenic transcription factors: therapeutic implications of endogenous STAT inhibitors. Trends Cancer. 2017;3:816–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Jiang M, Zhang WW, Liu P, Yu W, Liu T, Yu J. Dysregulation of SOCS-mediated negative feedback of cytokine signaling in carcinogenesis and its significance in cancer treatment. Front Immunol. 2017;8:70.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Yoshimura A, Ito M, Chikuma S, Akanuma T, Nakatsukasa H. Negative regulation of cytokine signaling in immunity. Cold Spring Harb Perspect Biol. 2018;10:a028571.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  28. Pauli EK, Schmolke M, Wolff T, Viemann D, Roth J, Bode JG, et al. Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. PLoS Pathog. 2008;4:e1000196.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Zhang X, You Q, Zhang X, Chen X. SOCS3 methylation predicts a poor prognosis in HBV infection-related hepatocellular carcinoma. Int J Mol Sci. 2015;16:22662–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Gargan S, Ahmed S, Mahony R, Bannan C, Napoletano S, O’Farrelly C, et al. HIV-1 promotes the degradation of components of the type 1 IFN JAK/STAT pathway and blocks anti-viral ISG induction. EBioMedicine. 2018;30:203–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Patel MR, Dash A, Jacobson BA, Ji Y, Baumann D, Ismail K, et al. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models. Cancer Gene Ther. 2019;26:411–8.

    Article  CAS  PubMed  Google Scholar 

  32. Hensen L, Hoeben R, Bots S. Adenovirus receptor expression in cancer and its multifaceted role in oncolytic adenovirus therapy. Int J Mol Sci. 2020;21:6828.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. González-Pastor R, Ashshi A, El-Shemi A, Dmitriev I, Kashentseva E, Lu Z, et al. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents. J Ovarian Res. 2019;12:18.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Mesev EV, LeDesma RA, Ploss A. Decoding type I and III interferon signalling during viral infection. Nat Microbiol. 2019;4:914–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Sohn SY, Hearing P. Adenoviral strategies to overcome innate cellular responses to infection. FEBS Lett. 2019;593:3484–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Crosse KM, Monson EA, Beard MR, Helbig KJ. Interferon-stimulated genes as enhancers of antiviral innate immune signaling. J Innate Immun. 2018;10:85–93.

    Article  CAS  PubMed  Google Scholar 

  37. Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, Maurer MJ, et al. Constitutive interferon pathway activation in tumors as an efficacy determinant following oncolytic virotherapy. J Natl Cancer Inst. 2018;110:1123–32.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Pan C, Cai Q, Li X, Li L, Yang L, Chen Y, et al. Enhancing the HSV-1-mediated antitumor immune response by suppressing Bach1. Cell Mol Immunol. 2022;19:516–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Zhang H, Li K, Lin Y, Xing F, Xiao X, Cai J, et al. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci Transl Med. 2017;9:eaam7996.

    Article  PubMed  Google Scholar 

  40. Han Q, Zhou H, Xie W, Sun T, Wei R, Nie C, et al. Association between the methylation of the STAT1 and SOCS3 in peripheral blood and gastric cancer. J Gastroenterol Hepatol. 2020;35:1347–54.

    Article  CAS  PubMed  Google Scholar 

  41. Waldner MJ, Neurath MF. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Semin Immunol. 2014;26:75–9.

    Article  CAS  PubMed  Google Scholar 

  42. Cui Q, Jiang W, Wang Y, Lv C, Luo J, Zhang W, et al. Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma. Hepatology. 2008;47:105–12.

    Article  CAS  PubMed  Google Scholar 

  43. Iwahori K, Serada S, Fujimoto M, Nomura S, Osaki T, Lee CM, et al. Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma. Int J Cancer. 2011;129:1005–17.

    Article  CAS  PubMed  Google Scholar 

  44. Yoneda T, Kunimura N, Kitagawa K, Fukui Y, Saito H, Narikiyo K, et al. Overexpression of SOCS3 mediated by adenovirus vector in mouse and human castration-resistant prostate cancer cells increases the sensitivity to NK cells in vitro and in vivo. Cancer Gene Ther. 2019;26:388–99.

    Article  CAS  PubMed  Google Scholar 

  45. Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. 2018;128:1413–28.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Ma J, Ramachandran M, Jin C, Quijano-Rubio C, Martikainen M, Yu D, et al. Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. Cell Death Dis. 2020;11:48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Wu YY, Sun TK, Chen MS, Munir M, Liu HJ. Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response. Front Cell Infect Microbiol. 2023;13:1142172.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer. 2018;6:140.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Shalhout S, Miller D, Emerick K, Kaufman H. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20:160–77.

    Article  PubMed  Google Scholar 

  50. Bommareddy P, Shettigar M, Kaufman H. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018;18:498–513.

    Article  CAS  PubMed  Google Scholar 

  51. Wherry E. T cell exhaustion. Nat Immunol. 2011;12:492–9.

    Article  CAS  PubMed  Google Scholar 

  52. Liikanen I, Basnet S, Quixabeira D, Taipale K, Hemminki O, Oksanen M, et al. Oncolytic adenovirus decreases the proportion of TIM-3 subset of tumor-infiltrating CD8 T cells with correlation to improved survival in patients with cancer. J Immunother Cancer. 2022;10:e003490.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Feist M, Zhu Z, Dai E, Ma C, Liu Z, Giehl E, et al. Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. Cancer Gene Ther. 2021;28:98–111.

    Article  CAS  PubMed  Google Scholar 

  54. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med. 2000;6:1134–9.

    Article  CAS  PubMed  Google Scholar 

  55. Rodríguez-García A, Giménez-Alejandre M, Rojas J, Moreno R, Bazan-Peregrino M, Cascalló M, et al. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Clin Cancer Res. 2015;21:1406–18.

    Article  PubMed  Google Scholar 

Download references

Funding

Funding

The National Key Technology Research and Development Program of China (2022YFC2704200 and 2022YFC2704205); National Science and Technology Major Sub-Project (2018ZX10301402-002); Beijing Xisike Clinical Oncology Research Foundation (Y-2019AZZD-0359); National Natural Science Foundation of China (81772787, 82072889, 82103456); Technical Innovation Special Project of Hubei Province (2018ACA138); China Postdoctoral Science Foundation (2023M731198).

Author information

Authors and Affiliations

  1. Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China

    Danmei Yan, Guannan Li, Yuan Yuan, Huayi Li, Heng Cao, Yilin Dai, Ying Li, Zeyu Zhang, Fei Li, Yong Fang & Qinglei Gao

  2. National Clinical Research Center for Obstetrics and Gynecology, Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China

    Danmei Yan, Guannan Li, Yuan Yuan, Huayi Li, Heng Cao, Yilin Dai, Ying Li, Zeyu Zhang, Fei Li, Yong Fang & Qinglei Gao

  3. Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China

    Yuan Yuan

Authors
  1. Danmei Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guannan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuan Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huayi Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Heng Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yilin Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ying Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zeyu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yong Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Qinglei Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

QLG and YF conceived and designed the project, supervised the study and prepared the manuscript. DMY performed experimental work, interpreted the data, draft the work and prepared the manuscript. GNL performed experimental work and interpreted the data. YY, HC, YLD, YL, and ZYZ performed experimental work. HYL and FL contributed to language editing. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Yong Fang or Qinglei Gao.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethical approval

All animal experiments were approved by the Committee on Ethics of Animal Experiments of Tongji Hospital (TJH-202112004).

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yan, D., Li, G., Yuan, Y. et al. SOCS3 inhibiting JAK-STAT pathway enhances oncolytic adenovirus efficacy by potentiating viral replication and T-cell activation. Cancer Gene Ther 31, 397–409 (2024). https://doi.org/10.1038/s41417-023-00710-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41417-023-00710-2

Search

Advanced search

Quick links